On December 10, 2025, MAIA Biotechnology, Inc. announced its new approach to target the $50 billion immunotherapy market with a breakthrough telomere-targeting method.
AI Assistant
MAIA BIOTECHNOLOGY INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.